Please assess the completion status of the following clinical trial:

Trial Title: Testis CAB: Cabazitaxel as Salvage Treatment for Cisplatin-resistant Germ Cell Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male patients ≥ 18 years old~* Histologically verified metastatic germ cell cancer (GCC) of the testicle or extragonadal GCC originating from retroperitoneum or mediastinum~* Disease progression during cisplatin-based chemotherapy or Disease progression or relapse after high-dose chemotherapy or Disease progression or relapse after at least 2 different cisplatin-based regimens~* Eastern Cooperative Oncology Group (ECOG) Performance Status (PS): 0-2~* Life expectancy ≥ 3 months~* At baseline adequate function of liver, kidneys and bone marrow:~·Neutrophils ≥ 1.5 x 109/L·~* Hemoglobin ≥ 9.0 g/dL~* Platelets ≥ 100 x 109/L~* Creatinine ≤ 1.5 x upper limit of normal (ULN)~* Total Bilirubin ≤ 1.0 x ULN~* Serum glutamate oxaloacetate transaminase (SGOT/AST) ≤ 1.5 x ULN~* Serum glutamate pyruvate transaminase (SGPT/ALT) \< 1.5 x ULN~Exclusion Criteria:~* Systemic antitumor treatment within 21 days before study entry~* Simultaneous radiotherapy to the only target lesion~* Patients unwilling or unable to comply with the protocol~* Patients with unstable angina pectoris, myocardial infarction ≤ 6 months prior to first study treatment, congestive heart failure New York Heart Association (NYHA) III-IV or serious uncontrolled cardiac arrhythmias~* Patients with an active or uncontrolled infection~* Patients who have a history of another primary malignancy and are off treatment for ≤ 3 years, with the exception of non-melanoma skin cancer~* Patients who have undergone major surgery within 4 weeks prior to starting study drug (e.g. intra-thoracic, intra-abdominal, or intra-pelvic) or significant traumatic injury, or who have not recovered from the side effects of any of the above within 6 weeks~* Patients who have participated in another interventional clinical trial within 30 days before study entry~* Other serious medical conditions that could impair the ability of the patient to participate in the study~* Active infection requiring systemic antibiotic-, anti-viral-, or anti-fungal medication~* Neuropathy ≥Grade 2 Common Terminology Criteria for Adverse Events (CTCAE)~* Patient with reproductive potential not implementing accepted and effective method of contraception during the whole study period and up to 6 months after the last dose of cabazitaxel~* One or more of the following cabazitaxel-specific requirements:~  * History of severe hypersensitivity reaction (≥ Grade 3) to docetaxel~ * History of severe hypersensitivity reaction (≥ Grade 3) to polysorbate 80 containing drugs~ * Concurrent or planned treatment with strong inhibitors or strong inducers of cytochrome P450 3A4 (CYP3A4) (a one week wash-out period is necessary for patients who are already on these treatments) (see Appendix A and B)~ * Concurrent or planned treatment with Organic anion transporting polypeptide1B1 (OATP1B1) substrates e.g. statins, valsartan, repaglinide which have to be taken within 12 hours before cabazitaxel application and 3 hours after the end of infusion, refer table 9

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cabazitaxel (single arm study) (Type: EXPERIMENTAL): Cabazitaxel 25 mg/m2 each 3. week (no other drugs will be administered)

Based on this trial design, predict the completion outcome and termination type (if applicable).